al Saati T, Tkaczuk J, Krissansen G, Print C, Pileri S, Ralfkiaer E, Grogan T M, Meggetto F, Delsol G
Department of Pathology and CIGH/CNRS, CHU-Purpan, Toulouse, France.
Blood. 1995 Oct 1;86(7):2741-6.
A novel antigen detected by the CBF.78 monoclonal antibody (MoAb) is strongly expressed on cortical thymocytes and weakly expressed on resting peripheral T lymphocytes. Expression of the antigen is increased on phytohemagglutinin (PHA)- and anti-CD3-activated T lymphocytes and on Epstein-Barr virus-transformed B lymphocytes. The CBF.78 immunoprecipitated a protein of 116 kD from resting and PHA-activated peripheral blood mononuclear cells. CBF.78 MoAb did not inhibit T-cell proliferation induced by anti-CD3 antibody. This MoAb was effective for immunostaining on paraffin sections after microwave-oven heating of tissue sections. Among malignant lymphomas, the antigen recognized by CBF.78 MoAb was found to be mainly expressed by T-cell lymphomas (49+ of 74), particularly those of high-grade malignancy (31+ of 36), whereas only occasional B-cell lymphomas (4+ of 107) expressed the antigen. A distinctive pattern of reactivity was shown by 108 cases of anaplastic large cell lymphomas. Strong positivity for CBF.78 antibody was observed in 86+ of 108 cases, irrespective of B, T, or null phenotype. This multicenter study suggests that CBF.78 MoAb could be of diagnostic value in differentiating Hodgkin's-like anaplastic large cell lymphomas from cases of Hodgkin's disease rich in neoplastic cells. Only a few cases of Hodgkin's disease (13+ of 126) showed rare Reed-Sternberg cells that stained, In these few cases, staining was weak to moderate and confined to cytoplasm. CBF.78 MoAb was nonreactive with all nonhematopoietic neoplasms examined (0+ of 48). Further studies should delineate the function of this new antigen and its clinical utility.
由CBF.78单克隆抗体（MoAb）检测到的一种新型抗原在皮质胸腺细胞上强烈表达，而在静止的外周T淋巴细胞上弱表达。该抗原在植物血凝素（PHA）和抗CD3激活的T淋巴细胞以及爱泼斯坦-巴尔病毒转化的B淋巴细胞上表达增加。CBF.78从静止和PHA激活的外周血单核细胞中免疫沉淀出一种116kD的蛋白质。CBF.78 MoAb不抑制抗CD3抗体诱导的T细胞增殖。该MoAb在对组织切片进行微波炉加热后对石蜡切片进行免疫染色有效。在恶性淋巴瘤中，发现CBF.78 MoAb识别的抗原主要由T细胞淋巴瘤表达（74例中的49例），尤其是高级别恶性肿瘤（36例中的31例），而只有偶尔的B细胞淋巴瘤（107例中的4例）表达该抗原。108例间变性大细胞淋巴瘤显示出独特的反应模式。108例中的86例观察到CBF.78抗体强阳性，无论其B、T或无表型如何。这项多中心研究表明，CBF.78 MoAb在将霍奇金样间变性大细胞淋巴瘤与富含肿瘤细胞的霍奇金病病例区分开来方面可能具有诊断价值。只有少数霍奇金病病例（126例中的13例）显示罕见的里德-斯腾伯格细胞染色，在这些少数病例中，染色为弱至中度且局限于细胞质。CBF.78 MoAb与所有检测的非造血肿瘤均无反应（48例中的0例）。进一步的研究应阐明这种新抗原的功能及其临床应用。
